Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Total Operating Expense: ¥608.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688319 Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
73 GF Score
Price ¥27.01
GF Value ¥23.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Chengdu Olymvax Biopharmaceuticals Total Operating Expense?

Chengdu Olymvax Biopharmaceuticals SHSE:688319 +0.33% 73 Total Operating Expense is ¥608.5 Mil as of Mar. 2026. GuruFocus rates SHSE:688319 with a GF Score™ of 73/100 and a GF Value™ of ¥23.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Chengdu Olymvax Biopharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was ¥115.4 Mil. Chengdu Olymvax Biopharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥608.5 Mil.

Chengdu Olymvax Biopharmaceuticals Total Operating Expense Related Terms

Chengdu Olymvax Biopharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Chengdu Olymvax Biopharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Olymvax Biopharmaceuticals Total Operating Expense Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 351.93 452.80 450.92 518.21 583.13

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.97 141.98 154.40 196.78 115.38
SHSE:688319
73GF Score
Chengdu Olymvax Biopharmaceuticals Inc SHSE:688319
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Olymvax Biopharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥608.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ¥608.5 Mil mean?
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Total Operating Expense of ¥608.5 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors.
Is Chengdu Olymvax Biopharmaceuticals' Total Operating Expense too high?
Chengdu Olymvax Biopharmaceuticals' current Total Operating Expense is ¥608.5 Mil. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Total Operating Expense compare to VRTX and REGN?
Chengdu Olymvax Biopharmaceuticals' Total Operating Expense of ¥608.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current Total Operating Expense is ¥608.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.01 — trading 16.8% above its estimated fair value. The current Total Operating Expense is ¥608.5 Mil. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Total Operating Expense is ¥608.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued. The current stock price of ¥27.01 is trading 16.8% above its estimated GF Value™ of ¥23.13. GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.

Key valuation signals for SHSE:688319:

  • Total Operating Expense: ¥608.5 Mil
  • GF Value™: ¥23.13 vs. price of ¥27.01 (16.8% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Olymvax Biopharmaceuticals Business Description

Address 99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score

Get the complete analysis for SHSE:688319

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.01
Price
¥23.13
GF Value